A novel regimen of vorinostat with interferon gamma for refractory Sézary syndrome.
Long-term prognosis for advanced stages of cutaneous T-cell lymphoma may be beneficially altered with the use of multimodality therapy. However, refractory disease exists in which current therapeutic options fail to halt the progression of disease. We present 3 cases of refractory Sézary syndrome in which the combination of vorinostat and interferon gamma was well tolerated and produced significant clinical improvement. The potential immunologic basis for this is discussed.
Gardner
Jennifer M
JM
Department of Dermatology, Hospital of the University of Pennsylvania, 3600 Spruce Street, Philadelphia, PA 19146, USA.
Introcaso
Camille E
CE
Nasta
Sunita D
SD
Kim
Ellen J
EJ
Vittorio
Carmela C
CC
Rook
Alain H
AH
D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D006877:Hydroxamic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012751:Sezary Syndrome / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy; D000077337:Vorinostat
D006877:Hydroxamic Acids; D000077337:Vorinostat; D007371:Interferon-gamma